A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naive Subjects With Follicular Non-Hodgkin's Lymphoma, Refractory or Relapsed After Previous Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2006
At a glance
- Drugs Aldesleukin; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 02 Sep 2005 New trial record.